NCT04966481View on ClinicalTrials.gov

Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor

PHASE3RecruitingINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

April 6, 2022

Primary Completion Date

February 28, 2028

Study Completion Date

February 28, 2028

Conditions
HPV-unrelated Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Palbociclib

Administered on an outpatient basis

DRUG

Cetuximab

Given intravenously over approximately 60 minutes

Trial Locations (4)

57104

RECRUITING

Sanford Medical Center, Sioux Falls

58122

RECRUITING

Sanford Roger Maris Cancer Center, Fargo

63110

RECRUITING

Washington University School of Medicine, St Louis

64111

RECRUITING

Saint Luke's Hospital, Kansas City

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

The Joseph Sanchez Foundation

UNKNOWN

lead

Washington University School of Medicine

OTHER

NCT04966481 - Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor | Biotech Hunter | Biotech Hunter